Melanoma Staging and Prognosis: TNM Classification, Breslow Depth, and Survival Outcomes

Clinical Overview

Accurate staging of melanoma is essential for prognostic counseling, treatment decision-making, and surveillance planning. The tumor, node, metastasis (TNM) classification system, updated to the 8th edition in 2017 by the American Joint Committee on Cancer (AJCC), provides a standardized framework for staging cutaneous melanoma based on histopathologic and clinical findings. TNM staging integrates Breslow depth (vertical thickness in millimeters), Clark level (invasion depth into dermal layers), mitotic rate, ulceration status, sentinel lymph node (SLN) biopsy results, and presence of distant metastases. This staging system allows reliable stratification of patients into prognostic groups, guides adjuvant therapy decisions, and enables comparison of outcomes across institutions and clinical trials.

Epidemiology & Risk Factors

Melanoma incidence has increased approximately 3% annually in the United States over the past two decades, though this increase is primarily in early-stage disease attributable to improved detection and screening awareness. The distribution of melanoma by stage at diagnosis varies geographically: in developed countries with robust dermatology services, approximately 85-90% of melanomas are Stage I-II (localized disease), while developing countries present with higher proportion of advanced-stage disease. Factors influencing stage at presentation include: patient awareness and skin self-examination practices, access to dermatology care, provider education regarding melanoma recognition, and presence of risk factors (prior melanoma history).

Pathophysiology

TNM staging reflects the pathophysiology of melanoma progression from localized to regional to distant disease. Breslow depth serves as the most important prognostic factor because it correlates with the probability of occult lymph node and distant metastases. Thin melanomas (≤1mm) have <5% risk of SLN positivity, while thick melanomas (>4mm) have 25-40% risk. Clark level indicates the anatomic invasion into dermal layers: Level I (in situ) has virtually zero metastatic risk, while Level IV (invasion into reticular dermis) carries significant nodal metastasis risk. Mitotic rate reflects melanoma cell proliferation activity: ≥1 mitosis per mm² indicates aggressive biology and increases stage within each Breslow depth category. Ulceration represents tumor necrosis breaking through the overlying epidermis and indicates aggressive phenotype, reducing survival by approximately 10% within each stage group. SLN positivity indicates regional metastatic disease (Stage III) and is the single most important prognostic factor beyond the primary tumor, reducing 5-year survival by 25-40% depending on tumor burden.

Clinical Presentation & Classification

TNM Stage IA melanoma (Breslow ≤0.8mm, Clark level I-II, no ulceration, mitotic rate <1/mm²) has excellent prognosis with 5-year melanoma-specific survival >95% and 10-year survival approaching 90%. These thin melanomas have minimal risk of metastasis; SLN biopsy is not routinely performed. Stage IB encompasses Breslow 0.81-1.0mm without ulceration or ≤1.0mm with ulceration, with 5-year survival 90-95%. Stage IIA includes Breslow 1.01-2.0mm without ulceration with 5-year survival 80-85%. Stage IIB encompasses Breslow 2.01-4.0mm without ulceration or 1.01-2.0mm with ulceration, with 5-year survival 65-75%. Stage IIC includes Breslow >4.0mm with or without ulceration, with 5-year survival 40-50%. Stage III represents regional metastatic disease with variable prognosis based on nodal burden: IIIA (occult SLN micrometastases) has 5-year survival 60-75%, IIIB (1-3 macroscopic nodes) has 5-year survival 40-50%, and IIIC (≥4 nodes) has 5-year survival 20-30%. Stage IV (distant metastases) has median survival 8-12 months without treatment, improving with immunotherapy and targeted agents.

Diagnosis & Staging

Accurate histopathologic assessment is essential for TNM staging. Breslow depth is measured from the granular layer of the epidermis to the deepest point of melanoma invasion, using an ocular micrometer on the microscope. Clark level is assessed from I (in situ) to V (subcutaneous fat invasion). Mitotic rate is counted as number of mitoses per 1.0 mm² in the most mitotically active area. Ulceration is defined as epidermal discontinuity overlying the tumor. Tumor infiltrating lymphocyte (TIL) response is assessed (absent, non-brisk, brisk) and is prognostically relevant. Margins of the specimen are examined for tumor involvement. Sentinel lymph node biopsy is indicated for Breslow 0.8-4.0mm to determine if SLN is involved, which changes staging from Stage I-II to Stage IIIA-IIIC. SLN biopsy involves: (1) lymphoscintigraphy with radioactive tracer to identify draining basin(s), (2) intraoperative mapping and blue dye injection, (3) removal of identified SLN(s), and (4) detailed pathologic examination including routine histology, immunohistochemistry, and serial sectioning to detect micrometastases. SLN positivity is approximately: 5% for Breslow 0.8-1.0mm, 15-20% for Breslow 1.01-2.0mm, 30-40% for Breslow 2.01-4.0mm, and 40-50% for Breslow >4.0mm.

Treatment Algorithm

Treatment depends on TNM stage: Stage IA-IB localized melanoma is treated with wide local excision alone (0.5-1.0cm margins). Stage IIA-IIC localized melanoma is treated with wide local excision and SLN biopsy; if SLN is negative, observation is routine, though adjuvant therapy may be discussed. If SLN is positive (Stage IIIA-IIIC), completion lymph node dissection is performed, and adjuvant immunotherapy is strongly recommended: ipilimumab 3mg/kg IV every 3 weeks for 4 doses induction, then maintenance (EORTC 18071, CheckMate 069) improves recurrence-free survival from 50% to 70% at 3 years. Alternatively, pembrolizumab 200mg IV every 3 weeks for up to 1 year similarly improves RFS (KEYNOTE-054). For BRAF-mutant Stage III disease, dabrafenib 100mg twice daily plus trametinib 2mg daily improves RFS compared to observation. For distant metastatic disease (Stage IV), systemic therapy is indicated: pembrolizumab or nivolumab (monotherapy response rates 40-50%), or combination nivolumab-ipilimumab (response rates 60%, median OS >60 months in responders).

Prognosis & Survival

Survival depends primarily on TNM stage: Stage IA (≤0.8mm) has 95% 5-year and 90% 10-year survival. Stage IB (0.81-1.0mm or ≤1.0mm with ulceration) has 90-95% 5-year and 87-90% 10-year survival. Stage IIA (1.01-2.0mm, no ulceration) has 80-85% 5-year and 75-80% 10-year survival. Stage IIB (2.01-4.0mm, no ulceration) has 65-75% 5-year and 60-70% 10-year survival. Stage IIC (>4.0mm, any ulceration) has 40-50% 5-year and 35-45% 10-year survival. Stage IIIA (occult SLN micrometastases) has 60-75% 5-year and 50-65% 10-year survival. Stage IIIB (1-3 macroscopic nodes) has 40-50% 5-year survival. Stage IIIC (≥4 nodes) has 20-30% 5-year survival. Stage IV (distant metastases) has median survival 8-12 months without treatment, 18-24 months with immunotherapy. Adjuvant immunotherapy improves recurrence-free survival by 25-30% for Stage IIIA-IIIC disease.

When to See a Dermatologist

Patients with newly diagnosed melanoma require dermatology and oncology consultation for staging assessment and treatment planning. After initial treatment, surveillance intervals depend on stage: Stage I patients require annual dermatology examination with monthly skin self-examination. Stage II patients require examination every 3-6 months. Stage III patients require examination every 3 months for the first 2 years, then every 3-6 months. Stage IV patients typically have baseline imaging (CT chest/abdomen/pelvis) and regular oncology follow-up every 4-12 weeks depending on treatment.

Frequently Asked Questions

My melanoma is 1.5mm Breslow depth. What stage is it, and what's my prognosis?

A melanoma with 1.5mm Breslow depth is Stage IIA (assuming no ulceration and no SLN involvement). Five-year survival for Stage IIA is 80-85%. You should have SLN biopsy to determine if lymph nodes are involved; if SLN is negative, prognosis is excellent with 85-90% 10-year survival.

What does it mean if my sentinel lymph node biopsy is positive?

SLN positivity indicates regional metastatic disease—melanoma cells have spread to lymph nodes, changing your stage from localized (I-II) to regional (Stage III). This substantially changes treatment and prognosis. You will typically have completion lymph node dissection and should receive adjuvant immunotherapy for 1-2 years. With adjuvant therapy, recurrence-free survival improves significantly.

I have Stage IIIB melanoma with 2 positive lymph nodes. Will adjuvant therapy improve my outcome?

Yes. Stage IIIB with limited nodal involvement has 5-year survival of 40-50% with observation alone. Adjuvant immunotherapy with pembrolizumab or ipilimumab improves recurrence-free survival by 25-30%, resulting in approximately 65-70% 2-year recurrence-free survival.

My Breslow depth is 4.2mm (Stage IIC). Is my prognosis hopeless?

No. Stage IIC melanoma has 5-year survival of 40-50% without adjuvant therapy, but with complete surgical excision and adjuvant immunotherapy, outcomes improve substantially. Modern immunotherapy and targeted therapy options offer meaningful survival benefit. Regular surveillance allows earlier detection of any recurrence.

References

  1. Gershenwald JE, Scolyer M, Khatri R, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472-492.
  2. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19(16):3622-3634.
  3. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23-34.
  4. Weber JS, Carlino MS, Khattak A, et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus placebo plus pembrolizumab in resected melanoma (KEYNOTE-942). Lancet. 2022;400(10368):1682-1696.
  5. Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo in resected Stage III IIM melanoma (EORTC 18071). Lancet Oncol. 2015;16(5):522-530.
  6. Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377(19):1813-1823.
  7. Sladden MJ, Balch C, Barzilai DA, et al. Surgical excision margins for primary cutaneous melanoma. J Am Acad Dermatol. 2012;66(3):395-404.
  8. Swetter SM, Tsao H, Bichakjian CK, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2019;80(1):208-250.
  9. Dummer R, Hauschild A, Lindenblatt N, Pentheroudakis G, Khattak A. Cutaneous melanoma: ESMO Clinical Practice Guidelines. Ann Oncol. 2015;26(5):v126-v132.
  10. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer staging system. J Clin Oncol. 2001;19(16):3622-3634.

Last updated: March 2026. This article reflects current evidence-based clinical practice and is intended for healthcare professionals and informed patients. Always consult with a board-certified dermatologist for personalized medical advice.